您的位置：首页 > 产品中心 > 93479-97-1， 格列美脲
格列美脲
Glimepiride
| 产品编号： | 4118940 |
| 规格： | British Pharmacopoeia (BP) Reference Standard |
| CAS NO： | 93479-97-1 |
| 包装规格： | 100 MG |
| 产品类别： | 进口试剂 |
| 优惠价： | 立即咨询 |
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4118940 | 100 MG | 458 |
产品别名
93479-97-1
格列美脲
Glimepiride
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C24H34N4O5S |
| Molecular weight | 490.62 |
| MDL number | MFCD00878417 |
| NACRES | NA.24 |
| General description【一般描述】 | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. |
| Application【应用】 | 格列美脲目前用于治疗 2 型糖尿病。 |
| Biochem/physiol Actions【生化/生理作用】 | 格列美脲是一种有效的心肌梗死 KATP 通道阻断剂，被吡那地尔激活，IC50 值为 6.8 nM。 |
| Other Notes【其他说明】 | Sales restrictions may apply. |
产品性质
| grade【等级】 | pharmaceutical primary standard |
| manufacturer/tradename | BP |
| format【格式】 | neat |
| storage temp.【储存温度】 | 2-8℃ |
| SMILES string | CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O |
| InChI | 1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19- |
| InChI key | WIGIZIANZCJQQY-RUCARUNLSA-N |
| Gene Information | human ... ABCC8(6833), KCNJ11(3767) |
| packaging【包装】 | Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia |
安全信息
| Pictograms【象形图】 | GHS08 |
| Signal word【警示用语：】 | Warning |
| Hazard Statements | H361 |
| Precautionary Statements | P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| Hazard Classifications【危险分类】 | Repr. 2 |
| Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
| WGK | WGK 3 |
